EUVIMEDEUVIMED entdecken
Crossref

BHLHE41 Enhances Gemcitabine Sensitivity of Pancreatic Cancer Cells Through IGFBP4 Suppression

Hisaaki Shii, Kentaro Minami, Ryu Takeya, Ryuji Ikeda

Anticancer Research · 2026

DOI: 10.21873/anticanres.17936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Hisaaki Shii und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Miyazaki Hospital, Miyazaki, Japan. Hauptthemen laut MEDLINE: Deoxycytidine, Pancreatic Neoplasms, Basic Helix-Loop-Helix Proteins, Drug Resistance, Neoplasm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Pancreatic cancer (PC) has a poor prognosis and limited treatment options. The development of resistance to anticancer agents poses a significant challenge in the treatment of PC. Our previous study indicated that basic helix-loop-helix family member e41 (BHLHE41) is associated with the prognosis of lung cancer. Additionally, BHLHE41 affects the prognosis and response to anticancer drugs in several cancers. However, the functional role of BHLHE41 in cancer remains unclear. In PC, its expression has been reported to influence tumor malignancy; however, its impact on chemosensitivity has not yet been elucidated. Therefore, this study aimed to investigate the effects of BHLHE41 on PC chemosensitivity. MATERIALS AND METHODS: Genetic modification and MTT assays were performed to evaluate the effect of BHLHE41 on anticancer agents. RNA sequencing (RNA-seq) was conducted to analyze the downstream pathways of BHLHE41. Furthermore, anticancer agent sensitivity tests were performed for the candidate genes identified through RNA-seq. RESULTS: BHLHE41 enhanced the sensitivity of PC cells to gemcitabine (GEM) while suppressing the expression of insulin-like growth factor binding protein 4 (IGFBP4). Additionally, IGFBP4 affected sensitivity to GEM independently of BHLHE41, suggesting that IGFBP4 contributes to resistance to this agent in PC cells. CONCLUSION: These findings provide novel insights that may help identify potential targets for patients with PC undergoing chemotherapy and open new avenues for research and therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidinePancreatic NeoplasmsBasic Helix-Loop-Helix ProteinsDrug Resistance, NeoplasmAntimetabolites, AntineoplasticHumansGemcitabineCell Line, TumorGene Expression Regulation, NeoplasticCell Proliferation

Stichwörter der Autor:innen

BHLHE41GemcitabineIGFBP4pancreatic cancerresistancesensitivity

Substanzen

GemcitabineDeoxycytidineBasic Helix-Loop-Helix ProteinsAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Pharmacy, University of Miyazaki Hospital, Miyazaki, Japan.
  • Department of Pharmacy, University of Miyazaki Hospital, Miyazaki, Japan; kentaro_minami@med.miyazaki-u.ac.jp.
  • Department of Pharmacology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Department of Pharmacy, University of Miyazaki Hospital, Miyazaki, Japan; ryuji_ikeda@med.miyazaki-u.ac.jp.

Zitieren

APA

Shii, H., Minami, K., Takeya, R., & Ikeda, R. (2026). BHLHE41 Enhances Gemcitabine Sensitivity of Pancreatic Cancer Cells Through IGFBP4 Suppression. Anticancer Research. https://doi.org/10.21873/anticanres.17936

Vancouver

Shii H, Minami K, Takeya R, Ikeda R. BHLHE41 Enhances Gemcitabine Sensitivity of Pancreatic Cancer Cells Through IGFBP4 Suppression. Anticancer Research. 2026. doi:10.21873/anticanres.17936

BibTeX
@article{Shii2026,
  author = {Shii, Hisaaki and Minami, Kentaro and Takeya, Ryu and Ikeda, Ryuji},
  title = {BHLHE41 Enhances Gemcitabine Sensitivity of Pancreatic Cancer Cells Through IGFBP4 Suppression},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.17936}
}
Kostenlos starten →